

# Dementia with Lewy bodies and Alzheimer's disease: an unfortunate couple?

<https://www.neurodegenerationresearch.eu/survey/dementia-with-lewy-bodies-and-alzheimers-disease-an-unfortunate-couple/>

## **Name of Fellow**

Dr. A.W. Lemstra

## **Institution**

### **Funder**

ZonMw

## **Contact information of fellow**

### **Country**

The Netherlands

## **Title of project/programme**

Dementia with Lewy bodies and Alzheimer's disease: an unfortunate couple?

## **Source of funding information**

ZonMw

## **Total sum awarded (Euro)**

€ 149,490

## **Start date of award**

01/10/15

## **Total duration of award in years**

4.0

## **The project/programme is most relevant to:**

Alzheimer's disease & other dementias

## **Keywords**

Dementia with Lewy Bodies | concomittant AD-pathology | longitudinal cohort | biomarkers | genetics

## **Research Abstract**

Dementia with Lewy Bodies (DLB) is a devastating neurodegenerative disease that is the second most common form of dementia. Up to 50-80% of patients with DLB have coexisting AD-pathology (amyloid and tau depositions). Up till now surprisingly very little research has been performed to study the cause or clinical relevance of AD-copathology in DLB. Aggregated evidence from postmortem studies suggests an added effect of AD-pathology on clinical manifestation and disease progression in DLB. But it is questionable how we can translate postmortem data to our patient in daily clinical practice. With current state-of the art biomarkers techniques it is now feasible to detect AD-pathology during life, most effectively by CSF-analysis of disease-specific proteins, i.e amyloid-beta and tau. With CSF we can detect AD-pathology in early stages of disease. We have already shown in a large series of DLB-patients that a substantial portion of patients have a CSF-profile compatible with AD. The overall aim of this project is to investigate the clinical relevance of AD-pathology in early stages of DLB and to understand the biological factors that contribute to this effect, in order to improve care and offer personalized treatment strategies for DLB-patients. AD-pathology is detected by CSF-biomarkers.

**Types:**

Fellowships

**Member States:**

Netherlands

**Diseases:**

Alzheimer's disease & other dementias

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A